Phenotypes associated with this allele

• Allele Symbol: Prkch^tm1Cda
• Allele Name: targeted mutation 1, Kazuhiro Chida
• Allele ID: MGI:2663731
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Prkch^tm1Cda/Prkch^tm1Cda	B6.129S-Prkch^tm1Cda	MGI:3848492
hm2	Prkch^tm1Cda/Prkch^tm1Cda	involves: 129S/SvEv * C57BL/6J	MGI:2663732

Genotype
MGI:3848492

hm1

• Allelic Composition: Prkch^tm1Cda/Prkch^tm1Cda
• Genetic Background: B6.129S-Prkch^tm1Cda

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

delayed wound healing ( J:83498 )

• homozygotes of both sexes show a ~2-day delay in wound healing of punched skin relative to wild-type and heterozygous control mice

• however, contraction of the wound is completed within 5 days of injury, similar to wild-type and heterozygous control mice

impaired wound healing ( J:83498 )

• on day 14 after dorsal skin injury by punch biopsy, homozygotes display impaired epithelial regeneration, with extensive hyperplasia and papilla structure of epithelial tissues, ongoing inflammation, and numerous leukocytes and PCNA-positive fibroblasts in the repaired dermis; in contrast, wild-type and heterozygous control mice display full recovery of the tissue structure on day 12 after injury

Genotype
MGI:2663732

hm2

• Allelic Composition: Prkch^tm1Cda/Prkch^tm1Cda
• Genetic Background: involves: 129S/SvEv * C57BL/6J

mortality/aging

postnatal lethality, incomplete penetrance ( J:83498 )

• 3.8% of homozygotes exhibit fatal abnormalities at ~2 weeks of age

• however, the remaining ~96% are healthy and of normal weight, with no obvious differences in breeding, feeding, and social activity up to >30 months of age

growth/size/body

decreased body weight ( J:83498 )

• at ~2 weeks of age, 3.8% of homozygotes display a reduced body weight that is one-third of that observed in wild-type mice

vision/eye

abnormal eyelid aperture ( J:83498 )

• 3.8% of homozygotes exhibit defective eyelid opening

neoplasm

increased incidence of tumors by chemical induction ( J:83498 )

• in a two-stage skin carcinogenesis model, where tumor formation is initiated with DMBA (100 g) and promoted by repeated topical applications of TPA (10 g) once a week for 20 weeks, homozygotes are significantly more susceptible to papilloma formation than wild-type and heterozygous control mice

• however, tumor formation is not enhanced by DMBA or TPA treatment alone

increased skin papilloma incidence ( J:83498 )

• in a two-stage skin carcinogenesis model, homozygotes develop papillomas at 8 weeks of TPA promotion with a tumor incidence of 78% and 4.3 tumors/mouse at 20 weeks of promotion, whereas wild-type and heterozygous control mice develop papillomas at ~10 weeks of promotion and display both reduced tumor incidences (22% and 17%, respectively) and fewer tumors (0.39 and 0.28 tumor/mouse, respectively) at 20 weeks of promotion

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:83498 )

• in a two-stage skin carcinogenesis model, where tumor formation is initiated with DMBA (100 g) and promoted by repeated topical applications of TPA (10 g) once a week for 20 weeks, homozygotes are significantly more susceptible to papilloma formation than wild-type and heterozygous control mice

• however, tumor formation is not enhanced by DMBA or TPA treatment alone

integument

epidermal hyperplasia ( J:83498 )

• after a single topical application of TPA (10 g), homozygotes exhibit prolonged epidermal hyperplasia that lasts up to 10 days, whereas in wild-type mice epidermal thickness returns to basal levels within 7 days of TPA treatment

increased skin papilloma incidence ( J:83498 )

• in a two-stage skin carcinogenesis model, homozygotes develop papillomas at 8 weeks of TPA promotion with a tumor incidence of 78% and 4.3 tumors/mouse at 20 weeks of promotion, whereas wild-type and heterozygous control mice develop papillomas at ~10 weeks of promotion and display both reduced tumor incidences (22% and 17%, respectively) and fewer tumors (0.39 and 0.28 tumor/mouse, respectively) at 20 weeks of promotion